83802-73-7

Usage

Bicyclic compound

Indenol base structure It is a fluorinated derivative of indenol, which is a bicyclic compound commonly found in organic chemistry.

Physical appearance

White to off-white solid The compound has a white to off-white color and a solid state at room temperature.

Odor

Faint The compound has a very subtle and weak odor.

Solubility

Sparingly soluble in water The compound does not dissolve easily in water.

Primary use

Intermediate in synthesis It is mainly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.

Potential applications

Research and development The compound may have potential applications in the research and development of new chemical processes.

Safety precautions

Handle and store according to regulations Due to its structural properties and functional groups, it is important to handle and store 1H-Inden-5-ol, 6-fluoro-2,3-dihydro- with appropriate safety precautions and in accordance with regulations for handling hazardous chemicals.

Upstream product

• 83802-72-6 6-fluoro-5-methoxyindan 
• 1470-94-6 5-hydroxy-2,3-dihydro-1H-indene 
• 83802-70-4 3-(3-fluoro-4-methoxyphenyl)propionyl chloride 
• 83802-71-5 5-fluoro-6-methoxy-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 2676865-61-3 6-fluoro-5-isopropyl-2,3-dihydro-1H-inden-4-amine 
• 2676865-60-2 6-fluoro-4-nitro-5-(prop-1-en-2-yl)-2,3-dihydro-1H-indene 
• 2676865-58-8 6-fluoro-4-nitro-2,3-dihydro-1H-inden-5-ol 

Relevant academic research and scientific papers

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

ATG7 INHIBITORS AND THE USES THEREOF

Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

Synthesis and antianxiety activity of (ω-piperazinylalkoxy)indan derivatives

A series of (ω-piperazinylalkoxyl)indan derivatives has been synthesized and screened for potential antianxiety activities. The effect of structural modification of these molecules on activities has been systematically examined. Antianxiety activity was displayed by 5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (2), 5-[3-(4-[4-fluorophenyl)-1-piperazinyl]propoxy]indan (8), 6-fluoro-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (33), and 6-methyl-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (42), as determined in antifighting and anti-morphine tests. These derivatives in antianxiety tests were equipotent or more potent than chloridazepoxide with less muscle-relaxant effect. They also showed weak neuroleptic-like action.